Canakinumab in a subgroup of patients with COVID-19
Ucciferri, C., Auricchio, A., Di Nicola, M., Potere, N., Abbate, A., Cipollone, F. ... & Falasca, K. (2020). Canakinumab in a subgroup of patients with COVID-19. https://www.thelancet.com/action/showPdf?pii=S2665-9913%2820%2930167-3
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Neurological Associations of COVID-19
Endothelial cell infection and endotheliitis in COVID-19
Clinical impact of COVID-19 on patients with cancer
Hyperinflammatory shock in children during the COVID-19 pandemic
COVID-19 Cytokine Storm: the interplay between inflammation and coagulation
COVID-19: consider cytokine storm syndrome and immunosuppression
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study
Canakinumab in a subgroup of patients with COVID-19
Cerebral Micro-Structural Changes in COVID-19 Patients - An MRI-based 3-month Follow-up Study
COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study
Human recombinant soluble ACE2 in severe COVID-19
Association between high serum total cortisol concentrations and mortality from COVID-19